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Abstract
Introduction This study had three aims: to establish the
incidence of ipsilateral breast tumour recurrence (IBTR) in a
community treatment setting, to evaluate known factors – in
particular younger age (< 40 years) – predictive for local
recurrence, and to assess the impact of local recurrence on
disease-specific survival (DSS).
Methods A consecutive series of 1,540 women with node-
negative breast cancer, diagnosed between the ages of 18–75
years, were prospectively accrued between September 1987
and September 1999. All had undergone a resection of the
primary breast cancer with clear margins, an axillary lymph node
dissection with a minimum of four sampled nodes, and breast-
conserving surgery (of any type).
Results During the study follow-up period, 98 (6.4%) IBTRs
and 117 (7.6%) deaths from or with breast cancer were
observed. The median time to IBTR was 3.1 years and to death
from or with disease was 4.3 years. In the multivariate Cox
proportional hazards (PH) regression model for IBTR with
adjuvant therapy factors, independent risk factors included age
< 40 years (relative risk (RR) = 1.89, 95% confidence interval
(CI) of 1.00 – 3.58), presence of intraductal disease (RR = 1.81,
95% CI = 1.15–2.85) and histological grade ('G2' or G3 versus
G1: RR = 1.59, 95% CI = 0.87–2.94). In the multivariate Cox
PH regression model for DSS with adjuvant therapy factors,
independent risk factors included previous IBTR (RR = 2.58,
95% CI = 1.41–4.72), tumor size (1–2 cm versus < 1 cm: RR
= 1.95, 95% CI = 1.05–3.64, > 2 cm versus < 1 cm: RR = 2.94,
95% CI = 1.56–5.56), progesterone receptor status (negative
or equivocal versus positive or unknown: RR = 2.15, 95% CI =
1.36–3.39), lymphatic invasion (RR = 1.78, 95% CI = 1.17–
2.72), and histological grade ('G2' or G3 versus G1: RR = 8.59,
95% CI = 2.09–35.36). The effects of competing risks could be
ignored.
Conclusion The Cox PH analyses confirmed the importance of
known risk factors for IBTR and DSS in a community treatment
setting. This study also revealed that the early occurrence of an
IBTR is associated with a relatively poor five-year survival rate.
BCS = breast-conserving surgery; CI = confidence interval; DSS = disease-specific survival; IBTR = ipsilateral breast tumour recurrence; PH = pro-
portional hazards; RR = relative risk.Breast Cancer Research    Vol 8 No 4    Nottage et al.
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Introduction
Breast-conserving surgery (BCS) has been a standard of care
for some considerable time [1,2]. Local recurrence after mas-
tectomy is associated with low 5-year survival rates of 22 to
40% [3-5]. However, the relationship between local recur-
rence after BCS and metastatic disease or survival is more
complex. Local recurrence in these women is often amenable
to salvage therapy (that is, mastectomy or further BCS), and
early randomized trials of BCS versus mastectomy, or BCS
with and without radiation, demonstrated that survival is com-
parable despite rates of local recurrence in women treated
with BCS alone of 25% [6-8] to 35% [9]. Further analysis of
the pivotal National Surgical Adjuvant Breast and Bowel
Project B06 trial showed that local recurrence was a strong
predictor of reduced survival, but it seemed to act as a marker
for unfavourable disease rather than as a source for the devel-
opment of metastases [10]. This trial reported that women
experiencing local recurrence had a relative risk (RR) for devel-
oping distant disease 3.41-fold that of women free of local
recurrence.
In comparison with clinical trial participants, community-based
observational patient cohorts may provide enhanced general-
izability. Beginning in 1987, we have followed a consecutive
series of 1,540 women with node-negative breast cancer
treated at eight Toronto hospitals [11]. Women in this series
were treated in accordance with the community standards of
the time. Because, overall, women with node-negative disease
have favourable prognoses, analysis of local recurrence is
more straightforward than in node-positive women, in whom
high rates of metastatic disease present a strong competing
risk. With a minimum of 2.3 years of follow-up, we used this
large prospectively accrued cohort to estimate the incidence
of local recurrence and determine its effect on disease-spe-
cific survival (DSS). As a secondary question, we investigated
the effect of patient age on these outcomes.
Materials and methods
Patient eligibility, measured features and clinical follow-up
Women aged 18 to 75 years with node-negative breast can-
cer were accrued from September 1987 until September
1999. To be eligible for this prospective study, women had to
have undergone a resection of a primary breast cancer with
clear margins, and an axillary lymph node dissection with a
minimum of four sampled nodes, based on pathology review.
The median number of nodes removed was 11; the number of
nodes removed ranged from 4 to 38 nodes. All patients with
T2 tumours underwent staging with the use of bone scan,
abdominal ultrasound/abdominal computed tomographic scan
and chest X-ray. Eligible women were invited to participate by
their treating physician. Written informed consent was
obtained and final eligibility was based on chart review. Exclu-
sion criteria included inadequate assessment of histological
grade, inadequate staging, synchronous breast primary
tumours, surgeon or patient refusal, or previous malignancies.
For the purposes of this present report we included only
women who had undergone BCS (of any type) and had any
follow-up information.
Patient and pathological features recorded, as reported previ-
ously [11], included age, menopausal status, tumour size and
grade, endothelial space invasion, multicentricity (two or more
separate (usually) invasive primary breast cancers), hormone
receptor status, and presence of in situ disease.
Treatment and subsequent follow-up data were collected in a
standardized format. Charts were reviewed every 3 months
during the first 2 years after diagnosis, every 6 months until 5
years after diagnosis, and every year thereafter. Follow-up for
this report was terminated as of 10 January 2002, with an
additional 6 months allowed for verification purposes. The time
interval from the median participant entering the study to the
termination date for analysis was 10.9 years. Follow-up data
collected for each patient included treatment received, local
and distant recurrences, and cause of death, with the corre-
sponding dates. Local and distant recurrences were con-
firmed by review of reports or imaging conducted by MEB.
Statistical analyses
A total of 1,540 women met the eligibility criteria for this report.
Descriptive statistics compared the frequency distribution of
measured patient and pathological features between groups
defined by age (age < 40 years versus age ≥ 40 years).
Ipsilateral breast tumour recurrence and disease-
specific survival
The two outcomes of interest in this study are time to local
recurrence (ipsilateral breast tumour recurrence; IBTR) and
time to death with or from disease. Both invasive and intraduc-
tal IBTRs were included as events for the analysis of local
recurrence. Deaths from and with disease defined events for
DSS. Only prognostic factors previously identified in the liter-
ature were evaluated in the statistical analyses. Univariate sur-
vival analysis of each measured prognostic factor was
conducted via the log-rank test with Kaplan–Meier curves and
via the likelihood ratio statistic for Cox proportional hazards
(PH) models [12-14].
Patients currently lost to follow-up (n = 26) were censored at
their last known follow-up time for either event of interest. Cen-
soring for IBTR could also occur for three reasons. IBTR-free
women were censored at their death date (death from any
cause) or at the study termination date. In addition, women
who experienced a distant metastasis within 12 weeks before
a diagnosis of IBTR (n = 10) were censored for IBTR at their
diagnosis date for the distant metastasis [15]. This time frame
includes only women with an isolated IBTR and eliminates
those who had a synchronous systemic recurrence because
this might lead to a secondary finding of an IBTR. Deaths from
or with breast cancer were included in the analysis of DSS,Available online http://breast-cancer-research.com/content/8/4/R44
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whereas women who died for other reasons (n = 80) were
censored at their death times.
Using a Cox PH model, statistically significant (p ≤ 0.05) or
borderline significant (p < 0.1) prognostic factors identified
from the univariate survival analyses, together with factors
selected for hypothesis testing, were evaluated in multivariable
survival models. Because any form of treatment (radiotherapy,
hormonal or chemotherapy) can be a confounding factor with
patient and pathological features, all forms of treatment were
forced into the final model. To evaluate the hypothesis that
younger women (age < 40 years) experienced a higher rate of
IBTR than older women (age ≥ 40 years), this factor was
included in the multivariate modelling process for IBTR out-
come as well. Pairwise interactions between the factor for
young age and each of the other factors associated with IBTR
were assessed separately in bivariate models that also
included both variables. However, because very few younger
women (age < 40 years) experienced a local recurrence (12
of 98), most interactions could not be evaluated because of
inadequate power (results not shown).
The effect of time dependence of an IBTR on survival was
taken into account in the statistical analyses of DSS by mod-
elling IBTR as a time-dependent covariate in the multivariable
Cox PH models. In addition, the landmark method [16] was
used to estimate survival after an IBTR; the landmark time of
1.7 years since surgery was chosen because half of the 14
women who had both outcomes had experienced an IBTR by
this time. However, by 1.7 years from surgery, 20 women with-
out IBTR were excluded from the estimation of the DSS curves
on the basis of IBTR status because some had already died
from or with disease (n = 8) or were censored (n = 12).
Model assessment and competing risks
The proportional hazards assumption was assessed graphi-
cally and formally with a trend test statistic [17]. Scaled Sch-
oenfeld residuals were plotted against survival time for each
factor separately and for all variables combined in the multivar-
iate model. A Loess smoothing curve was used for visually
detecting trends over time. A formal global test of proportion-
ality for all factors included in a model was based on a χ2 dis-
tribution for testing for a trend between the scaled Schoenfeld
residuals and survival time.
In this study, women could experience one or both of the
events of interest during follow-up: an IBTR, and death from or
with breast cancer. If a woman does experience an IBTR, her
risk for dying can be altered. Similarly, if a woman experiences
a distant recurrence and subsequently dies from or with breast
cancer, she is not really at risk for IBTR and so should not be
treated as simply censored in any time-to-IBTR analyses. The
competing risks between developing an IBTR and dying from
or with disease were evaluated by modelling the cumulative
incidence function for each event of interest [14] and fitting
the proportional subdistribution hazards regression models
[18]. The first approach estimates the probability of the event
of interest when the patient is subject to the other event with-
out adjusting for the effect of covariates, whereas the second
approach directly assesses the effects of covariates on the
subdistribution of an event of interest in a competing risks set-
ting. To assess the potential impact of these competing risks
on our analyses, we compared estimates of the survivor func-
tion and regression coefficients calculated ignoring or explic-
itly modelling the competing risk.
All analyses were conducted with SAS/STAT® software (Ver-
sion 8.2) SAS System for Unix [19] and R software (version
2.1) [20].
Results
Patient, tumour, and adjuvant treatment characteristics
Nearly two-thirds of the 1,540 eligible patients were postmen-
opausal at diagnosis (Table 1), and most (91.7%) were 40
years of age or older (mean 56.1 years, SD 11.3 years).
Tumours were generally small, with 66% being 2 cm or less.
The younger women tended to have larger tumours (larger
than 2 cm), to be negative or equivocal for hormone receptor
status, and to have grade 3 (G3) tumours.
Most but not all of the patients received radiotherapy. The
treatment field was nearly always only the breast area (98%).
Just under 50% received adjuvant hormonal therapy and
15.5% received adjuvant chemotherapy; the proportion
receiving adjuvant systemic therapy increased over time.
Tamoxifen was the sole hormone therapy for 741 of the 758
women who received this adjuvant therapy. The predominant
(196 of 239) chemotherapy regimen was CMF (cyclophos-
phamide–methotrexate–5-fluorouracil). The type of systemic
adjuvant therapy differed with age, with younger women
receiving less hormonal therapy (18% versus 52%) and more
chemotherapy (43% versus 13%) than the older women.
Younger women who were oestrogen receptor-positive were
about half as likely to receive hormone therapy as older women
who were oestrogen receptor-positive (31% versus 57%;
data not shown).
Incidence of IBTR
The incidence of an isolated local recurrence was 6% (n = 98)
in this community-based study. The median time to IBTR was
3.1 years (SD 2.4), with nearly two-thirds (62 of 98) occurring
within 4 years from surgery (Figure 1). Of the 98 IBTRs, 27
were classified as intraductal and 71 as invasive. In the Kap-
lan–Meier estimate of the time to IBTR stratified according to
age at diagnosis (age < 40 years versus age ≥ 40 years), the
two curves begin to separate at about 5 years after surgery
(Figure 2). The percentage free of IBTR at 8.3 years was 88%
for younger women (age < 40 years), in comparison with 93%
for older women (age ≥ 40 years), which, however, is not sig-
nificant based on a simple log-rank test statistic (p = 0.47).Breast Cancer Research    Vol 8 No 4    Nottage et al.
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Table 1
Patient, tumour and treatment characteristics
Characteristic All eligible Age < 40 years Age ≥ 40 years
Number of patients 1,540 128 1,412
Number of IBTRs 98 12 86
Number of deaths (from or with disease) 117 12 105
Characteristic Number (%) Number (%) Number (%)
Menopausal status
Pre- or perimenopausal 544 (35.3) 127 (99.2) 417 (29.5)
Postmenopausal 996 (64.7) 1 (0.8) 995 (70.5)
Size of tumour
Less than 1.0 cm 319 (20.7) 15 (11.7) 304 (21.5)
1 to 2 cm 689 (44.7) 43 (33.6) 646 (45.8)
2 to 5 cm 516 (33.5) 64 (50.0) 452 (32.0)
Greater than 5 cm 16 (1.0) 6 (4.7) 10 (0.7)
Oestrogen receptor
Negative 242 (15.7) 46 (35.9) 196 (13.9)
Equivocal 67 (4.4) 14 (10.9) 53 (3.8)
Positive 858 (55.7) 57 (44.5) 801 (56.7)
Unknown/not done 373 (24.2) 11 (8.6) 362 (25.6)
Progesterone receptor
Negative 335 (21.8) 47 (36.7) 288 (20.4)
Equivocal 104 (6.8) 15 (11.7) 89 (6.3)
Positive 727 (47.2) 55 (43.0) 672 (47.6)
Unknown/not done 374 (24.3) 11 (8.6) 363 (25.7)
Histological grade
Grade 1 306 (19.9) 12 (9.4) 294 (20.8)
Grade '2' 563 (36.6) 38 (29.7) 525 (37.2)
Grade 3 428 (27.8) 62 (48.4) 366 (25.9)
Unknown/not done 243 (15.8) 16 (12.5) 227 (16.1)
Lymphatic invasion (1 unknown)
Yes 202 (13.1) 19 (14.8) 183 (13.0)
No 1,337 (86.8) 109 (85.2) 1,228 (87.0)
Vascular invasion (2 unknown)
Yes 55 (3.6) 6 (4.7) 49 (3.5)
No 1,483 (96.3) 122 (95.3) 1,361 (96.4)
Intraductal component (2 unknown)
Present 957 (62.2) 69 (53.9) 888 (62.9)
Absent 581 (37.7) 59 (46.1) 522 (37.0)
Multicentricity
Yes 95 (6.2) 8 (6.3) 87 (6.2)
No 1,437 (93.3) 119 (93.0) 1,318 (93.3)
Unknown/not done 8 (0.5) 1 (0.8) 7 (0.5)
Radiation therapy 1,300 (84.4) 118 (92.2) 1,182 (83.7)
Adjuvant treatment
Hormone therapy 758 (49.2) 23 (18.0) 735 (52.1)
Chemotherapy 239 (15.5) 55 (43.0) 184 (13.0)
Hormone and chemotherapy 55 (3.6) 5 (0.3) 50 (3.2)
IBTR, ipsilateral breast tumour recurrence.Available online http://breast-cancer-research.com/content/8/4/R44
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Prognostic factors for local recurrence
Factors associated with the risk of IBTR in univariate analysis
in this series (Table 2) included multicentricity and presence of
ductal carcinoma in situ. The apparent association between
histological grade not done or unknown and increased inci-
dence of IBTR is unexplained but may be related to different
pathology practices at the treating centres and unknown case-
mix variables, as the percentage of times that a histological
grade was not done or was unknown varied from 8.04% to
33.62% across the eight hospitals. As expected, women who
received radiotherapy experienced fewer local recurrences.
Hormone therapy and chemotherapy were also apparently
protective against IBTR but to a smaller extent.
Although the age < 40 years variable was not statistically sig-
nificant in the univariate Cox PH model, to assess the hypo-
thesis about the increased incidence of local recurrence in this
age group, this variable was also evaluated in a multivariate
model adjusting for the effects of other relevant factors. In a
multivariate model, age at diagnosis < 40 years and presence
of intraductal disease were found to be independently associ-
ated with IBTR, whereas adjuvant therapy (particularly radio-
therapy) was associated with reduced risk (Table 2).
Histological grade was also significant (likelihood ratio statis-
tic = 7.2 with 2 degrees of freedom, p = 0.027), but this was
apparently due to the association between IBTR and unknown
histological grade. The variable multicentricity lost significance
in the multivariate model, but because 11 of 12 women who
experienced an IBTR and had areas of multicentricity were
also classified as having ductal carcinoma in situ, the separate
effects of these variables on IBTR could not be evaluated in
these data.
Impact of IBTR on disease-specific survival
The diagnosis of an isolated IBTR significantly affected DSS.
In a univariate Cox PH model for DSS, IBTR had a RR of 3.04
(95% confidence interval (CI) = 1.72 to 5.35). This risk dimin-
ished only slightly (RR = 2.58, 95% CI = 1.41 to 4.72) in a
multivariable Cox PH model for DSS. In addition, we found that
an early IBTR diagnosis (within 1.7 years of surgery) resulted
in a very poor 5-year survival rate.
Twelve percent of the 117 women who died from or with dis-
ease during this study were diagnosed with a previous IBTR,
with an overall median time to death of 4.3 years (SD 2.5). Five
years after surgery, 67 of 117 deaths had occurred and the
percentage surviving was 95%. This percentage decreased to
87% by 12 years from surgery. With stratification on IBTR sta-
tus at the landmark time point (IBTR ≤ 1.7 years, IBTR > 1.7
years or no IBTR), Figure 3 reveals that the proportion surviv-
ing at 5 years is only 0.57 if the IBTR was diagnosed within 1.7
years from surgery (n = 15). In contrast to this poor survival
outcome, women diagnosed with an IBTR more than 1.7 years
from surgery (n = 83) or not diagnosed with an IBTR (n =
1,422) so far and alive at 1.7 years from surgery had 5-year
survival rates of 0.94. At the latest time of death (7.6 years) for
the early IBTR group, 38% were alive, which was significantly
less (log-rank test p ≤ 0.0001) than the 91% surviving in the
non-IBTR or IBTR > 1.7 years group. Inspection of the point-
wise test statistics reveals strong evidence that the group with
an IBTR diagnosed within 1.7 years from surgery has a hazard
rate different from that expected (χ2 = 47.2), with many more
observed deaths (7) than expected (0.81).
Figure 1
Kaplan–Meier estimate of ipsilateral breast tumour recurrence (IBTR) Kaplan–Meier estimate of ipsilateral breast tumour recurrence (IBTR).
Figure 2
Kaplan–Meier estimate of IBTR stratified by age under or over 40 years Kaplan–Meier estimate of IBTR stratified by age under or over 40 years. 
IBTR, ipsilateral breast tumour recurrence.Breast Cancer Research    Vol 8 No 4    Nottage et al.
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A multivariate Cox PH model for DSS (right side of Table 3)
was fitted including age at diagnosis (less than 40 years) and
IBTR occurrence as a time-dependent covariate, and using all
factors having weak statistical significance in univariate analy-
sis (left side of Table 3; p < 0.1) as well as the three treatment
variables. In contrast with the analysis of IBTR-free survival,
age at primary diagnosis < 40 years was not significant in the
multivariate model. The diagnosis of IBTR increased the risk of
death with or from breast cancer by 2.6. In this model, histo-
logical grade '2' or 3 was most strongly associated with the
risk of mortality, with a RR 8.6-fold that of histological grade 1.
Increasing tumour size and negative progesterone receptor
status also retained significance in the multivariate model.
However, the estimated RRs for the adjuvant treatment varia-
bles changed with adjustment for other factors in the multivar-
iate model, owing to the association of treatment received with
known prognostic factors [11].
Our investigation of patient age at diagnosis as a prognostic
factor for IBTR and DSS found that age was an important risk
factor for IBTR but not for DSS. The Kaplan–Meier survival
estimates of time to IBTR suggested differences between the
older (age ≥ 40 years) and younger (age < 40 years) women
Table 2
Results of IBTR-free survival analysis by univariate and multivariate Cox proportional hazards models
Prognostic variable Univariate Multivariate
RR 95% CI p RR 95% CI P
Age at primary diagnosisa 1.50 0.83–2.75 0.18 1.89 1.00–3.58 0.05
Intraductal (yes versus else) 1.69 1.09–2.64 0.02 1.81 1.15–2.85 0.01
Multicentricity (yes versus else) 2.10 1.15–3.84 0.02 1.54 0.83–2.85 0.17
Histological grade
'G2' & GG3 versus G1 1.39 0.76–2.53 0.29 1.59 0.87–2.94 0.13
Not done and don't know versus G1 2.50 1.29–4.85 0.01 2.40 1.23–4.67 0.01
Tumour size
1–2 cm versus <1 cm 1.12 0.70–1.80 0.64
>2 cm versus <1 cm 1.18 0.69–2.01 0.55
Oestrogen receptor statusb 0.87 0.52–1.47 0.61
Progesterone receptor statusb 1.46 0.97–2.21 0.07
Menopausal statusc 1.12 0.74–1.70 0.58
Vascular invasion (yes versus else) 0.59 0.15–2.39 0.46
Lymphatic invasion (yes versus else) 0.97 0.53–1.78 0.48
Radiation therapy versus none 0.30 0.20–0.45 <0.000001 0.29 0.19–0.44 <0.000001
Adjuvant treatment
Hormone therapy versus none 0.62 0.41–0.93 0.02 0.56 0.36–0.85 0.01
Chemotherapy versus none 0.47 0.22–1.02 0.06 0.45 0.20–1.02 0.06
98 IBTRs among 1,540 eligible women. IBTR, ipsilateral breast tumour recurrence; CI, confidence interval; RR, relative risk. aAge < 40 years 
versus age ≥ 40 years; bnegative and equivocal versus positive and don't know and not done; cpremenopausal and perimenopausal aged < 50 
years versus postmenopausal and perimenopausal aged ≥ 50 years.
Figure 3
Kaplan–Meier estimate of disease-specific survival by IBTR status at  1.7 years (τ) after surgery Kaplan–Meier estimate of disease-specific survival by IBTR status at 
1.7 years (τ) after surgery. IBTR, ipsilateral breast tumour recurrence.Available online http://breast-cancer-research.com/content/8/4/R44
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after 5 years of follow-up but the difference was not significant
on the basis of a log-rank test statistic (p = 0.47). Patient age
at diagnosis was statistically significant at the 5% level in a
multivariable Cox PH model for IBTR, with a RR of 1.89 (95%
CI = 1.00 to 3.58) but not in a univariate Cox PH model for
IBTR (RR = 1.50, 95% CI = 0.83 to 2.75).
Competing risks and model assessment
The differences between the two estimated cumulative inci-
dence curves were extremely small, suggesting that it is not
necessary to account for the competing risks when assessing
time-to-IBTR and DSS (data not shown).
We also fitted proportional subdistribution hazards regression
models of the final multiple variable models for time to IBTR
and DSS. The estimated parameters (coefficients and their
standard errors) and Wald statistic p values were compared
with those obtained from the standard Cox PH model. Gener-
ally, results were identical to two decimal places and there
were no real differences in the significance of the variables in
the final models (results not shown). Thus, the effects of the
competing risks could safely be ignored in this study.
A summary plot of the curves for the competing risks can show
how changes in the probability of one event can impact the
probability of the other event. In Figure 4, the IBTR cumulative
incidence and the sum of the IBTR and disease-specific death
cumulative incidences are plotted. At any given time, the
height of the lowest curve is the IBTR probability, the distance
between the two curves is the probability of dying from breast
cancer, and the distance from the top of the plot (1.0) to the
highest curve is the probability of being alive without IBTR. At
5 years the IBTR probability is 0.049, which is slightly higher
than the probability of dying from breast cancer (0.043); the
IBTR-free survival is 0.91. At the end of the study follow-up
period (14.3 years) the IBTR probability is 0.095, which is now
lower than the probability of dying from or with breast cancer
(0.119); the IBTR-free survival is reduced to 0.78.
Table 3
Results of disease-specific survival analysis by univariate and multivariate Cox proportional hazards models
Prognostic variable Univariate Multivariate
RR 95% CI p RR 95% CI p
Previous IBTR (yes versus else) 3.04 1.72–5.35 0.0001 2.58 1.41–4.72 0.002
Age at primary diagnosisa 1.17 0.64–2.13 0.61 0.79 0.42–1.46 0.45
Intraductal (yes versus else) 0.90 0.62–1.29 0.56
Multicentricity (yes versus else) 1.01 0.49–2.08 0.97
Histological grade
'G2' and G3 versus G1 14.64 3.64–58.9 0.006 8.59 2.09–35.36 0.003
Not done and don't know versus G1 7.86 1.81–34.2 0.0002 4.73 1.07–20.94 0.04
Tumour size
1–2 cm versus <1 cm 2.74 1.49–5.03 0.001 1.95 1.05–3.64 0.04
>2 cm versus <1 cm 4.97 2.71–9.12 < 0.00001 2.94 1.56–5.56 0.0009
Oestrogen receptor statusb 2.77 1.91–4.01 < 0.00001 1.23 0.75–2.04 0.41
Progesterone receptor statusb 3.56 2.47–5.14 < 0.00001 2.15 1.36–3.39 0.001
Menopausal statusc 1.18 0.81–1.72 0.38
Vascular invasion (yes versus else) 1.78 0.83–3.83 0.14
Lymphatic invasion (yes versus else) 2.35 1.55–3.57 0.00006 1.78 1.17–2.72 0.008
Radiation therapy versus none 1.19 0.70–2.01 0.53 1.18 0.67–2.09 0.57
Adjuvant treatment
Hormone therapy versus none 0.66 0.46–0.97 0.03 0.75 0.50–1.15 0.19
Chemotherapy versus none 1.47 0.92–2.36 0.11 0.62 0.36–1.05 0.07
117 deaths from or with disease among 1,540 eligible women. CI, confidence interval; IBTR, ipsilateral breast tumour recurrence; RR, relative risk. 
aAge < 40 years versus age ≥ 40 years; bnegative and equivocal versus positive and don't know and not done; cpremenopausal and 
perimenopausal aged < 50 years versus postmenopausal and perimenopausal aged ≥ 50 years.Breast Cancer Research    Vol 8 No 4    Nottage et al.
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The global test of proportional hazards for the IBTR multivari-
ate regression model was non-significant, as were univariate
tests for non-proportionality for each prognostic factor in this
model. Hence, there was no evidence that the proportional
hazards assumptions were not met. For the disease-specific
multivariate regression model, however, the global test of pro-
portional hazards was significant, indicating evidence against
this assumption. Two variables in this final model, oestrogen
receptor status and hormone therapy, also showed evidence
of non-proportionality. Plots of the scaled Schoenfeld residu-
als along with a fitted linear spline indicated that being
negative or equivocal for oestrogen receptor status was asso-
ciated with higher death rates for about the first 5 years after
surgery but not thereafter. Hormone therapy also had a nega-
tive trend in these plots; the apparent benefit of this therapy
developed slowly and did not appear until nearly 5 years from
surgery. Thus, the estimated RRs for these time-dependent
factors represent an average effect over the follow-up time
(results not shown).
Discussion
Our study adds to the literature on local recurrence after BCS
in four respects. First, the incidence of local recurrence (6%)
in this community setting is comparable to that seen in clinical
trial data. This level was achieved despite the fact that 15% of
our patients did not receive radiotherapy. Because therapy
was at the discretion of the treating physician, we assume that
radiotherapy was not thought necessary or suitable for these
women. Second, the median time to IBTR of 3.1 years closely
parallels that (46 months) seen in a similarly treated, node-
negative cohort as published by Cowen and colleagues [21].
Third, in multivariate analysis, we found that young age (less
than 40 years) was associated with a risk of local recurrence
of 1.89 times that of older women. The only other factor to
retain significance in a multivariate analysis was the presence
of intraductal disease. However, some variables occurred
infrequently, resulting in low power to detect an association.
Finally, this observational study is consistent with the 15-year
update of the National Surgical Adjuvant Breast and Bowel
Project B06 trial in which age < 40, presence of an intraductal
component as well as nuclear grade were independently asso-
ciated with the time to IBTR [22].
The 5-year overall survival after IBTR in women treated with
BCS is between 50 and 75% [21,23-27]. Our data demon-
strate once again that an early local recurrence after conserv-
ative surgery is associated with poorer DSS (DSS at over 9
years from surgery is 91%, versus 38%). In this series, lym-
phatic invasion, large tumour size, high histological grade, neg-
ative hormone receptor status and presence of local
recurrence were each associated with reduced DSS in a mul-
tivariate model. This effect has been noted by Veronesi and
colleagues (failure within 2 years) [26], Whelan and col-
leagues (failure within 1 year) [27] and Haffty and colleagues
(failure within 4 years) [23].
Young women have previously been found to have a worse
prognosis than older women, in terms of increased rates of
both local recurrence [28-30] and mortality [31-33]. Although
close to nominal statistical significance, we did observe an
increased incidence of local recurrence in women under 40
years old (9.4%). These young women had increased rates of
other unfavourable prognostic factors (larger tumour size,
higher tumour grade). Because only one woman in this
younger age group had a local recurrence and subsequently
died from or with breast cancer, it was not possible to deter-
mine whether higher rates of local recurrence contribute to
their poorer survival.
The competing risk analysis revealed that, in this study, the
effects of the competing risks could be ignored. The summary
plot of the cumulative incidences of IBTR and death from or
with breast cancer (Figure 4) showed how the probability of
developing an IBTR versus dying from breast cancer changes
over the time since surgery. After surgery, women have a
greater likelihood of developing a local recurrence. However,
as the length of time since surgery increases, the likelihood of
dying from or with breast cancer exceeds the likelihood of
developing a local recurrence.
Conclusion
Our results support published data on factors associated with
local recurrence, including the impact of early-onset breast
cancer. We also demonstrate that the early occurrence of
IBTR is associated with a relatively poor 5-year DSS of only
57%. The repeated identification of this adverse effect sug-
gests that women with early local recurrence should be tar-
gets for clinical studies of 'pseudo-adjuvant' systemic therapy.
Figure 4
Competing risks between ipsilateral breast tumour recurrence (IBTR)  and disease-specific survival Competing risks between ipsilateral breast tumour recurrence (IBTR) 
and disease-specific survival.Available online http://breast-cancer-research.com/content/8/4/R44
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